Replies to post #5392 on Manhattan Scientifics Inc (MHTX)

[ssc]

I'm guessing when you say MRI you mean the MRX machine based on the Flynn technology, yes?

Regarding dilution, share-based compensation is not the big concern. It's the fact that human trials have not even been applied for and the many years and many millions of dollars of costs that lie between the first FDA trials and actual bankable results. At 4 cents/share every million dollars raised equals 25 million new shares. If they are forced to resort to convertible notes as they have done in the past, it could easily be double that amount. Being optimistic and saying just 3 more years until some type of success, at $1 million/quarter that would equate to between 300 million and 600 million new shares. Sounds significant to me. On the less optimistic side, after all these years they are still unable to produce results that merit submitting a request to the FDA to simply begin a trial.